Detailed information about the 100 most recent patent applications.
| Application Number | Title | Filing Date | Disposal Date | Disposition | Time (months) | Office Actions | Restrictions | Interview | Appeal |
|---|---|---|---|---|---|---|---|---|---|
| 17054448 | PROPHYLACTIC AND/OR THERAPEUTIC AGENT FOR INFLAMMATORY DISEASES WHICH CONTAINS PYRROLOPYRIMIDINE COMPOUND AS ACTIVE INGREDIENT | July 2021 | June 2024 | Allow | 43 | 1 | 0 | No | No |
| 17135927 | BENZYL AMINE-CONTAINING HETEROCYCLIC COMPOUNDS AND COMPOSITIONS USEFUL AGAINST MYCOBACTERIAL INFECTION | December 2020 | June 2023 | Allow | 30 | 0 | 1 | Yes | No |
| 17122442 | BIEMAMIDES AND RELATED SCAFFOLDS AS INHIBITORS OF TRANSFORMING GROWTH FACTOR-BETA SIGNALING | December 2020 | November 2022 | Allow | 23 | 0 | 0 | No | No |
| 17122542 | sGC STIMULATORS | December 2020 | March 2024 | Abandon | 39 | 0 | 1 | Yes | No |
| 17252483 | CANNABINOID COMPOSITION AND METHODS OF TREATMENT USING THE SAME | December 2020 | May 2024 | Allow | 41 | 1 | 0 | No | No |
| 17118807 | MULTI-TYROSINE KINASE INHIBITORS DERIVATIVES AND METHODS OF USE | December 2020 | November 2022 | Allow | 24 | 0 | 0 | No | No |
| 17118204 | NOVEL CRYPTOPHYCIN COMPOUNDS AND CONJUGATES, THEIR PREPARATION AND THEIR THERAPEUTIC USE | December 2020 | May 2024 | Abandon | 41 | 2 | 1 | No | No |
| 17116070 | BISPHENOL ETHER DERIVATIVES AND METHODS FOR USING THE SAME | December 2020 | May 2023 | Allow | 30 | 1 | 1 | No | No |
| 17113495 | [1,2,4]TRIAZOLO[1,5-A]PYRIDINYL SUBSTITUTED INDOLE COMPOUNDS | December 2020 | January 2023 | Allow | 26 | 0 | 1 | No | No |
| 16972335 | HEXAHYDROPYRROLO[3,4-C]PYRROLE DERIVATIVES USEFUL AS LOX INHIBITORS | December 2020 | February 2024 | Allow | 38 | 1 | 1 | No | No |
| 17108663 | KDM1A INHIBITORS FOR THE TREATMENT OF DISEASE | December 2020 | November 2022 | Allow | 24 | 0 | 0 | No | No |
| 15734074 | PYRAZOLOPYRIMIDINE COMPOUNDS AS ADENOSINE RECEPTOR ANTAGONISTS | December 2020 | June 2023 | Allow | 30 | 1 | 0 | No | No |
| 17104739 | COMBINATION THERAPY INVOLVING DIARYL MACROCYCLIC COMPOUNDS | November 2020 | January 2023 | Allow | 26 | 1 | 0 | Yes | No |
| 17103648 | 2-BENZOPYRAZINYL-N-HETEROARYL-2-PHENYL-ACETAMIDE COMPOUNDS | November 2020 | March 2023 | Allow | 27 | 1 | 0 | No | No |
| 16953989 | COMBINATION THERAPY COMPRISING AN ALK2 INHIBITOR AND A JAK2 INHIBITOR | November 2020 | April 2023 | Allow | 29 | 0 | 1 | No | No |
| 16952257 | PYRUVATE KINASE ACTIVATORS FOR USE IN TREATING BLOOD DISORDERS | November 2020 | March 2021 | Allow | 4 | 0 | 1 | No | No |
| 17099578 | COMPOUNDS FOR TREATING SPINAL MUSCULAR ATROPHY | November 2020 | July 2023 | Allow | 32 | 0 | 1 | No | No |
| 17055164 | PHARMACEUTICAL SALTS OF PYRIMIDINE DERIVATIVES AND METHOD OF TREATING DISORDERS | November 2020 | March 2024 | Allow | 40 | 1 | 0 | Yes | No |
| 17055067 | TREATMENTS | November 2020 | May 2024 | Allow | 42 | 1 | 1 | No | No |
| 17095729 | TRIAZOLOPYRIMIDINE COMPOUNDS AND THEIR USE IN TREATING CANCER | November 2020 | March 2021 | Allow | 5 | 0 | 1 | No | No |
| 17089415 | DOSING REGIMENS FOR USE IN TREATING MYELOFIBROSIS AND MPN-RELATED DISORDERS WITH NAVITOCLAX | November 2020 | April 2021 | Allow | 5 | 0 | 1 | Yes | No |
| 17088468 | PYRIDAZINONE COMPOUNDS AND USES THEREOF | November 2020 | April 2022 | Allow | 17 | 2 | 1 | Yes | No |
| 16949519 | Pyrazolo[4,3-d]pyrimidines as Antitumor Agents | November 2020 | October 2023 | Allow | 35 | 1 | 1 | No | No |
| 17084862 | PYRAZOLO-QUINAZOLINE DERIVATIVES, PROCESS FOR THEIR PREPARATION AND THEIR USE AS KINASE INHIBITORS | October 2020 | March 2024 | Abandon | 40 | 1 | 1 | Yes | No |
| 17051176 | QUINAZOLINE DERIVATIVES AS ANTITUMOR AGENTS | October 2020 | March 2023 | Allow | 28 | 1 | 1 | Yes | No |
| 17081477 | Small Molecule Inhibitors of KRAS G12C Mutant | October 2020 | January 2023 | Allow | 27 | 0 | 1 | Yes | No |
| 17077232 | NOVEL BENZYLAMINO SUBSTITUTED QUINAZOLINES AND DERIVATIVES AS SOS1 INHIBITORS | October 2020 | March 2024 | Allow | 41 | 2 | 1 | Yes | No |
| 17049439 | Poxvirus Host Range Protein K3 as a Positive Selection Marker for Generation of Recombinant Poxviruses, a Therapeutic Target for Poxvirus Infection and a Therapeutic Agent for PKR Related Diseases | October 2020 | November 2023 | Allow | 37 | 1 | 0 | No | No |
| 17049235 | METHOD OF USING MEK INHIBITOR TO PREVENT RADIATION INDUCED FIBROSIS | October 2020 | February 2024 | Allow | 40 | 1 | 1 | No | No |
| 17075199 | LANTHIONINE SYNTHETASE C-LIKE 2-BASED THERAPEUTICS | October 2020 | September 2022 | Allow | 23 | 1 | 1 | No | No |
| 17048604 | MACROCYCLIC KINASE INHIBITOR | October 2020 | November 2022 | Allow | 25 | 0 | 0 | No | No |
| 17065737 | LUTEINIZING HORMONE-RELEASING HORMONE RECEPTOR (LHRH-R) CONJUGATES AND USES THEREOF | October 2020 | June 2023 | Abandon | 33 | 1 | 1 | No | No |
| 17065316 | METHODS OF TREATING MYELOPROLIFERATIVE DISORDERS | October 2020 | December 2020 | Allow | 2 | 0 | 0 | No | No |
| 17061111 | POLYMORPHIC FORMS OF AFATINIB FREE BASE AND AFATINIB DIMALEATE | October 2020 | April 2022 | Allow | 19 | 1 | 0 | No | No |
| 17042786 | SELECTIVE ANTI-CANCER AGENT EFFECTIVE FOR PREVENTION AND TREATMENT | September 2020 | April 2021 | Allow | 7 | 2 | 0 | No | No |
| 17027922 | DIHYDROINDOLIZINONE DERIVATIVE | September 2020 | September 2022 | Allow | 24 | 0 | 0 | No | No |
| 17028640 | METHODS OF TREATING GASTROINTESTINAL STROMAL TUMORS | September 2020 | December 2020 | Allow | 3 | 0 | 1 | No | No |
| 16982817 | PRODRUGS OF FUSED-BICYCLIC C5aR ANTAGONISTS | September 2020 | January 2023 | Allow | 28 | 1 | 0 | No | No |
| 17023545 | SELECTIVE SULFONATION OF BENZODIAZEPINE DERIVATIVES | September 2020 | September 2022 | Allow | 24 | 1 | 0 | No | No |
| 17023597 | DNA-PK INHIBITORS | September 2020 | July 2023 | Allow | 33 | 2 | 1 | No | No |
| 16981826 | NEW COMPOUNDS WITH ENHANCED ANTI-TUMOR EFFECTS | September 2020 | May 2022 | Allow | 20 | 0 | 0 | Yes | No |
| 16981208 | 3-hydroxy-N-(3-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)phenyl)pyrrolidine-1-carboxamide Derivatives | September 2020 | April 2022 | Allow | 19 | 0 | 0 | No | No |
| 17018816 | PREPARATIVE SCALE CONVERSION OF GONYAUTOXINS TO NEOSAXITOXIN | September 2020 | November 2020 | Allow | 2 | 0 | 0 | No | No |
| 16948312 | MTA-Cooperative PRMT5 Inhibitors | September 2020 | June 2022 | Allow | 21 | 1 | 0 | Yes | No |
| 17018738 | MTA-Cooperative PRMT5 Inhibitors | September 2020 | June 2022 | Allow | 21 | 1 | 0 | Yes | No |
| 17017023 | N-PYRIDINYL ACETAMIDE DERIVATIVES AS WNT SIGNALLING PATHWAY INHIBITORS | September 2020 | May 2022 | Allow | 21 | 2 | 0 | No | No |
| 17015696 | NOVEL MODULATORS OF THE 5-HYDROXYTRYPTAMINE RECEPTOR 7 AND THEIR METHOD OF USE | September 2020 | December 2021 | Allow | 16 | 0 | 0 | No | No |
| 17014883 | SPIRO AROMATIC RING COMPOUND AND APPLICATION THEREOF | September 2020 | January 2023 | Allow | 29 | 1 | 1 | No | No |
| 17013034 | HETEROCYCLIC RIP1 KINASE INHIBITORS | September 2020 | June 2022 | Allow | 21 | 1 | 1 | No | No |
| 17010182 | PYRIMIDINE COMPOUND | September 2020 | September 2022 | Allow | 25 | 1 | 1 | No | No |
| 16977654 | SERINE THREONINE KINASE (AKT) DEGRADATION / DISRUPTION COMPOUNDS AND METHODS OF USE | September 2020 | March 2022 | Allow | 19 | 0 | 0 | No | No |
| 16977775 | PYRIMIDINONE-CONTAINING COMPOUND, PREPARATION METHOD THEREOF, PHARMACEUTICAL COMPOSITION AND APPLICATION THEREOF | September 2020 | April 2022 | Allow | 20 | 1 | 0 | No | No |
| 16976882 | PYRAZOLE DERIVATIVES AS INHIBITORS OF THE WNT SIGNALLING PATHWAY | August 2020 | July 2022 | Allow | 23 | 1 | 1 | No | No |
| 17002748 | NOVEL PYRIMIDO[4,5-D]PYRIMIDIN-2-ONE DERIVATIVES AS PROTEIN KINASE INHIBITORS | August 2020 | October 2022 | Allow | 25 | 0 | 2 | No | No |
| 16971254 | SUBSTITUTED 1,2-DIHYDRO-3H-PYRAZOLO[3,4-D]PYRIMIDIN-3-ONES | August 2020 | July 2021 | Allow | 11 | 0 | 0 | No | No |
| 16997276 | NOVEL SUBSTITUTED QUINOLINE-8-CARBONITRILE DERIVATIVES HAVING ANDROGEN RECEPTOR DEGRADATION ACTIVITY AND USES THEREOF | August 2020 | December 2021 | Allow | 16 | 0 | 0 | No | No |
| 16993897 | 2-OXO-THIAZOLE DERIVATIVES AS A2A INHIBITORS AND COMPOUNDS FOR USE IN THE TREATMENT OF CANCERS | August 2020 | June 2022 | Allow | 22 | 0 | 1 | No | No |
| 16990657 | INHIBITORS OF THE MENIN-MLL INTERACTION | August 2020 | March 2023 | Allow | 31 | 1 | 1 | No | No |
| 16987322 | 1-PYRIDAZIN-/TRIAZIN-3-YL-PIPER(-AZINE)/IDINE/PYROLIDINE DERIVATIVES AND COMPOSITIONS THEREOF FOR INHIBITING THE ACTIVITY OF SHP2 | August 2020 | March 2022 | Allow | 19 | 1 | 0 | No | No |
| 16968038 | IRAK DEGRADERS AND USES THEREOF | August 2020 | July 2022 | Allow | 23 | 1 | 0 | Yes | No |
| 16984041 | OXOPIPERAZINE HELIX MIMETICS FOR CONTROL OF HYPOXIA-INDUCIBLE GENE EXPRESSION | August 2020 | September 2022 | Allow | 25 | 2 | 0 | No | No |
| 16940697 | COMPOUNDS AND COMPOSITIONS FOR IMMUNOTHERAPY | July 2020 | December 2022 | Allow | 28 | 1 | 1 | No | No |
| 16964885 | CRYSTALLINE FORMS OF THE CXCR7 RECEPTOR ANTAGONIST (3S,4S)-1-CYCLOPROPYLMETHYL-4-{[5-(2,4-DIFLUORO-PHENYL)-ISOXAZOLE-3-CARBONYL]-AMINO}-PIPERIDINE-3-CARBOXYLIC ACID (1-PYRIMIDIN-2-YL-CYCLOPROPYL)-AMIDE | July 2020 | January 2022 | Allow | 18 | 1 | 0 | No | No |
| 16936265 | Hydrazinyl-Substituted Heteroaryl Compounds and Methods for Producing a Conjugate | July 2020 | February 2022 | Allow | 19 | 0 | 1 | Yes | No |
| 16934803 | COMPOUNDS AND COMPOSITIONS FOR IMMUNOTHERAPY | July 2020 | December 2022 | Allow | 29 | 1 | 1 | No | No |
| 16933821 | Rapamycin 40-O-Cyclic Hydrocarbon Esters, Compositions and Methods | July 2020 | March 2022 | Allow | 20 | 2 | 0 | No | No |
| 16932987 | PHOSPHOINOSITIDE 3-KINASE AND SRC INHIBITORS FOR TREATMENT OF PANCREATIC CANCER | July 2020 | April 2022 | Allow | 21 | 0 | 1 | Yes | No |
| 16930911 | 1,2,4]TRIAZOLO[4,3-B]PYRIDAZINES FOR USE IN THE TREATMENT OF PROLIFERATIVE DISEASES | July 2020 | March 2022 | Allow | 20 | 1 | 0 | No | No |
| 16962347 | BROMODOMAIN INHIBITOR COMPOUND AND USE THEREOF | July 2020 | June 2022 | Allow | 23 | 0 | 1 | Yes | No |
| 16924763 | THERAPEUTIC COMPOUNDS | July 2020 | August 2022 | Allow | 26 | 1 | 1 | Yes | No |
| 16924033 | G1T38 SUPERIOR DOSAGE REGIMES | July 2020 | September 2021 | Allow | 15 | 0 | 0 | No | No |
| 16920752 | ANIMAL AND HUMAN ANTI-MALARIAL AGENTS | July 2020 | January 2022 | Allow | 18 | 1 | 0 | No | No |
| 16919001 | HETEROCYCLIC COMPOUNDS AS KINASE INHIBITORS | July 2020 | August 2022 | Allow | 26 | 1 | 1 | No | No |
| 16958721 | HETEROCYCLE COMPOUNDS AS TYRO3, AXL AND MERTK (TAM) FAMILY OF RECEPTOR TYROSINE KINASE INHIBITORS | June 2020 | March 2022 | Allow | 21 | 1 | 0 | No | No |
| 16913488 | TERTIARY ALCOHOLS AS PI3K-y INHIBITORS | June 2020 | August 2021 | Allow | 14 | 0 | 0 | No | No |
| 16913949 | SUBSTITUTED BENZYL-TRIAZOLE COMPOUNDS FOR CBL-B INHIBITION, AND FURTHER USES THEREOF | June 2020 | March 2022 | Allow | 21 | 0 | 1 | No | No |
| 16909686 | IMIDAZOTRIAZINES AND IMIDAZOPYRIMIDINES AS KINASE INHIBITORS | June 2020 | October 2021 | Allow | 16 | 0 | 0 | No | No |
| 16908604 | SPIRO AROMATIC RING COMPOUND AND APPLICATION THEREOF | June 2020 | August 2020 | Allow | 1 | 1 | 0 | Yes | No |
| 16956385 | Triazine Compounds substituted with Bulky Groups | June 2020 | August 2022 | Allow | 26 | 0 | 0 | No | No |
| 16955926 | PYRAZOLO[3,4-B]PYRIDINES AND IMIDAZO[1,5-B]PYRIDAZINES AS PDE1 INHIBITORS | June 2020 | August 2022 | Allow | 26 | 1 | 0 | Yes | No |
| 16955581 | Inhibitors of Protease Activated Receptor-2 | June 2020 | January 2023 | Allow | 31 | 1 | 1 | No | No |
| 16954320 | CYCLOHEXYL ACID PYRAZOLE AZOLES AS LPA ANTAGONISTS | June 2020 | February 2022 | Allow | 20 | 2 | 0 | No | No |
| 16772980 | PHARMACEUTICAL COMPOSITION FOR STIMULATING STEM CELL DIVISION AND SUPPRESSING BACTERIAL VIRULENCE | June 2020 | September 2021 | Allow | 15 | 1 | 1 | No | No |
| 16900616 | WNT SIGNALING PATHWAY INHIBITORS FOR TREATMENTS OF DISEASE | June 2020 | January 2023 | Allow | 31 | 1 | 1 | No | No |
| 16772253 | 5-(2,5-DIFLUOROPHENYL)PYRROLIDIN-1-YL)-3-(1H-PYRAZOL-1-YL)PYRAZOLO[1,5-A]PYRIMIDINE DERIVATIVES AND RELATED COMPOUNDS AS TRK KINASE INHIBITORS FOR TREATING CANCER | June 2020 | August 2021 | Allow | 14 | 0 | 0 | No | No |
| 16895735 | PEGYLATED PRODRUGS OF PHENOLIC TRPV1 AGONISTS | June 2020 | September 2021 | Allow | 15 | 0 | 0 | No | No |
| 16894010 | BRD4-KINASE INHIBITORS AS CANCER THERAPEUTICS | June 2020 | January 2023 | Allow | 31 | 1 | 1 | Yes | No |
| 16891417 | OXOPIPERAZINE DERIVATIVES | June 2020 | October 2021 | Allow | 16 | 1 | 1 | No | No |
| 16891160 | Use of Valbenazine for Treating Schizophrenia or Schizoaffective Disorder | June 2020 | January 2022 | Allow | 20 | 1 | 0 | No | No |
| 16889289 | NOVEL SUBSTITUTED QUINOLINE-8-CARBONITRILE DERIVATIVES HAVING ANDROGEN RECEPTOR DEGRADATION ACTIVITY AND USES THEREOF | June 2020 | August 2020 | Allow | 2 | 0 | 1 | Yes | No |
| 16885139 | COMPOUND, ORGANIC ELECTROLUMINESCENT DEVICE INCLUDING THE SAME AND ELECTRONIC APPARATUS | May 2020 | May 2023 | Allow | 36 | 0 | 1 | Yes | No |
| 16877284 | ACID ADDITION SALTS OF PIPERAZINE DERIVATIVES | May 2020 | September 2022 | Allow | 27 | 4 | 1 | Yes | No |
| 16764253 | PYRIDINIUM SALT AND PEST CONTROL AGENT | May 2020 | April 2022 | Allow | 23 | 2 | 0 | No | No |
| 16763746 | SMAC MIMETICS USED AS IAP INHIBITORS AND USE THEREOF | May 2020 | February 2022 | Allow | 21 | 1 | 0 | No | No |
| 15931437 | INHIBITORS OF BRUTON'S TYROSINE KINASE AND METHODS OF THEIR USE | May 2020 | December 2021 | Allow | 19 | 1 | 1 | No | No |
| 16762795 | METHOD FOR PREPARING BENZOFURAN DERIVATIVE | May 2020 | March 2022 | Allow | 22 | 0 | 1 | No | No |
| 16870418 | HETEROARYLAMINOPYRIMIDINE AMIDE AUTOPHAGY INHIBITORS AND METHODS OF USE THEREOF | May 2020 | March 2022 | Allow | 22 | 0 | 1 | Yes | No |
| 16869475 | SYNTHESIS OF LABELED IMIDAZO[1,2-A]PYRIMIDINES | May 2020 | January 2021 | Allow | 8 | 0 | 0 | No | No |
| 16869512 | REGIO-SELECTIVE SYNTHESIS OF IMIDAZO[1,2-a]PYRIMIDINES | May 2020 | December 2021 | Allow | 20 | 1 | 1 | No | No |
| 16869097 | MONOMERIC BIMETAL HYDROXYCITRIC ACID COMPOUNDS AND METHODS OF MAKING AND USING THE SAME | May 2020 | April 2021 | Allow | 11 | 1 | 0 | Yes | No |
This analysis examines appeal outcomes and the strategic value of filing appeals for examiner LEESER, ERICH A.
Filing a Notice of Appeal can sometimes lead to allowance even before the appeal is fully briefed or decided by the PTAB. This occurs when the examiner or their supervisor reconsiders the rejection during the mandatory appeal conference (MPEP § 1207.01) after the appeal is filed.
In this dataset, 50.0% of applications that filed an appeal were subsequently allowed. This appeal filing benefit rate is in the top 25% across the USPTO, indicating that filing appeals is particularly effective here. The act of filing often prompts favorable reconsideration during the mandatory appeal conference.
✓ Filing a Notice of Appeal is strategically valuable. The act of filing often prompts favorable reconsideration during the mandatory appeal conference.
Examiner LEESER, ERICH A works in Art Unit 1624 and has examined 756 patent applications in our dataset. With an allowance rate of 82.8%, this examiner has an above-average tendency to allow applications. Applications typically reach final disposition in approximately 18 months.
Examiner LEESER, ERICH A's allowance rate of 82.8% places them in the 57% percentile among all USPTO examiners. This examiner has an above-average tendency to allow applications.
On average, applications examined by LEESER, ERICH A receive 0.86 office actions before reaching final disposition. This places the examiner in the 5% percentile for office actions issued. This examiner issues significantly fewer office actions than most examiners.
The median time to disposition (half-life) for applications examined by LEESER, ERICH A is 18 months. This places the examiner in the 95% percentile for prosecution speed. Applications move through prosecution relatively quickly with this examiner.
Conducting an examiner interview provides a +15.4% benefit to allowance rate for applications examined by LEESER, ERICH A. This interview benefit is in the 54% percentile among all examiners. Recommendation: Interviews provide an above-average benefit with this examiner and are worth considering.
When applicants file an RCE with this examiner, 43.9% of applications are subsequently allowed. This success rate is in the 95% percentile among all examiners. Strategic Insight: RCEs are highly effective with this examiner compared to others. If you receive a final rejection, filing an RCE with substantive amendments or arguments has a strong likelihood of success.
This examiner enters after-final amendments leading to allowance in 75.0% of cases where such amendments are filed. This entry rate is in the 94% percentile among all examiners. Strategic Recommendation: This examiner is highly receptive to after-final amendments compared to other examiners. Per MPEP § 714.12, after-final amendments may be entered "under justifiable circumstances." Consider filing after-final amendments with a clear showing of allowability rather than immediately filing an RCE, as this examiner frequently enters such amendments.
This examiner withdraws rejections or reopens prosecution in 100.0% of appeals filed. This is in the 86% percentile among all examiners. Of these withdrawals, 100.0% occur early in the appeal process (after Notice of Appeal but before Appeal Brief). Strategic Insight: This examiner frequently reconsiders rejections during the appeal process compared to other examiners. Per MPEP § 1207.01, all appeals must go through a mandatory appeal conference. Filing a Notice of Appeal may prompt favorable reconsideration even before you file an Appeal Brief.
When applicants file petitions regarding this examiner's actions, 52.5% are granted (fully or in part). This grant rate is in the 50% percentile among all examiners. Strategic Note: Petitions show below-average success regarding this examiner's actions. Ensure you have a strong procedural basis before filing.
Examiner's Amendments: This examiner makes examiner's amendments in 5.2% of allowed cases (in the 87% percentile). Per MPEP § 1302.04, examiner's amendments are used to place applications in condition for allowance when only minor changes are needed. This examiner frequently uses this tool compared to other examiners, indicating a cooperative approach to getting applications allowed. Strategic Insight: If you are close to allowance but minor claim amendments are needed, this examiner may be willing to make an examiner's amendment rather than requiring another round of prosecution.
Quayle Actions: This examiner issues Ex Parte Quayle actions in 10.5% of allowed cases (in the 90% percentile). Per MPEP § 714.14, a Quayle action indicates that all claims are allowable but formal matters remain. This examiner frequently uses Quayle actions compared to other examiners, which is a positive indicator that once substantive issues are resolved, allowance follows quickly.
Based on the statistical analysis of this examiner's prosecution patterns, here are tailored strategic recommendations:
Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.
No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.
Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.
Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.